SAN RAFAEL - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the International Society for …
10 stocks we like better than BioMarin Pharmaceutical When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the …
* BIOMARIN DOSES FIRST PATIENT IN GLOBAL GENER8-1 PHASE 3 STUDY OF VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY FOR SEVERE HEMOPHILIA A Source text for Eikon: Further company coverage:
BioMarin Pharmaceutical Inc. announced its most recent results for valoctocogene roxaparvovec at the 2017 American Society of Hemophilia event over the weekend. Valoctocogene roxaparvovec is a treatment for severe hemophilia. “We …
The risk-reward has certainly improved, yet I am not pulling the trigger yet. BioMarin (BMRN) is a much debated stock even as its stock has been trading in a relative narrow $80-100 trading range so far this year, actually trading towards …
BioMarin showed signs of stagnation on revenue growth rate. The company just reported positive results for its drug candidates. The stock may continue its fluctuating performance in the absence of a near term catalyst. BioMarin